Figure 3

Neurodegeneration is prevented in the substantia nigra. Photomicrographs of TH immunoreactivity in substantia nigra demonstrate a noticeable decrease in TH immunoreactivity in the control groups (A) as compared to the groups that received 3 ng (B), 30 ng (C) and 90 ng of CX3CL1 (D). Bar denotes 0.2 mm. (E) Quantification of the number of TH⁺ cells in the substantia nigra shows a significant decrease of TH immunoreactivity in the substantia nigra of animals who receive HI CX3CL1 (control treatment) but this affect was reversed when animals received 3, and 90 ng exogenous soluble CX3CL1 through and osmotic minipump for 28 days one week after a lesion with 6-OHDA. One-way ANOVA, [F_(3,19) = 9.498, p = 0.0008]. Asterisk denotes significance (* P < 0.05) compare to HI-CX3CL1 group; † denotes significance († P < 0.05) compare to 90 ng CX3CL1 group as determined by Tukey post-hoc analysis. (F) Quantification of NeuN (neuronal nuclei marker) immunohistochemistry in substantia nigra shows a significant decrease in the HI-CX3CL1 control group as compared to the groups of animals treated with 3ng and 90 ng of CX3CL1. One-way ANOVA, [F_(3,19) = 7.359, p = 0.0026]. Asterisk denotes significance (* P < 0.05) of Tukey post-hoc analysis compare to HI-CX3CL1 group. (G) An increase in the number of OX-6⁺ cells in substantia nigra was found in the HI-CX3CL1 control group. CX3CL1This was significantly decreased by all three doses of CX3CL1. One-way ANOVA, [F_(3,19) = 19.04, P < 0.0001]. Asterisk denotes significance (* P < 0.05) compare to HI-CX3CL1 group by Tukey post-hoc analysis.